$6.24 Billion is the total value of Flagship Pioneering Inc.'s 33 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Sell | Moderna Inc | $2,695,084,000 | -16.4% | 20,581,016 | -33.3% | 43.16% | -26.5% |
| SANA | New | Sana Biotechnology Inc | $1,145,980,000 | – | 34,239,018 | +100.0% | 18.35% | – |
| RUBY | Buy | Rubius Therapeutics Inc | $1,020,423,000 | +251.1% | 38,506,526 | +0.5% | 16.34% | +208.9% |
| MCRB | Seres Therapeutics Inc | $302,137,000 | -16.0% | 14,673,973 | 0.0% | 4.84% | -26.1% | |
| EVLO | Buy | Evelo Biosciences Inc | $246,421,000 | -11.0% | 23,030,069 | +0.6% | 3.95% | -21.7% |
| SGTX | Sigilon Therapeutics Inc | $231,778,000 | -53.5% | 10,370,369 | 0.0% | 3.71% | -59.1% | |
| FHTX | Foghorn Therapeutics Inc | $167,045,000 | -35.0% | 12,674,120 | 0.0% | 2.68% | -42.8% | |
| KLDO | Buy | Kaleido Biosciences Inc | $158,562,000 | -10.0% | 19,575,710 | +1.1% | 2.54% | -20.8% |
| DNLI | Denali Therapeutics Inc | $155,898,000 | -31.8% | 2,730,263 | 0.0% | 2.50% | -40.0% | |
| AXLA | Axcella Health Inc | $59,729,000 | -8.3% | 12,548,414 | 0.0% | 0.96% | -19.3% | |
| CDAK | Codiak Biosciences Inc | $39,318,000 | -53.3% | 2,607,303 | 0.0% | 0.63% | -58.9% | |
| SYRS | Syros Pharmaceuticals Inc | $21,980,000 | -31.1% | 2,938,494 | 0.0% | 0.35% | -39.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.